the aid library

LIST OPTIONS

Filter

1842

Sort by:

Direction:

Download (1736)

View PDF (2230)

Infection Control Assessment Tool for Primary Health Care Facilities

SIAPS USAID (2013) C1

Nosocomial or health-facility-acquired infections are a serious issue, representing one of the most significant causes of morbidity and mortality in healthcare systems and consuming many scarce resources, especially in developing countries. Although much has been done, particularly in the hospital s... more

Download (1331)

View PDF (3228)

Infection Control Assessment Tool: A Standardized Approach for Improving Hospital Infection Control Practices

South Africa's Dept. of Health; USAID; SIAPS (2010) C1

The ICAT is a simple and practical approach for assessing the adequacy of existing infection prevention and control practices and provides specific recommendations for improving practices and monitoring their effectiveness over time

Download (1156)

View PDF (2572)

Guidelines on core components of infection prevention and control programmes
recommended

World Health Organization WHO (2016) C_WHO

at the national and acute health care facility level

Download (530)

View PDF (968)

Infection Prevention and Control Assessment Framework at the Facility Level
recommended

World Health Organization WHO (2018) C_WHO

The Infection Prevention and Control (IPC) Assessment Framework (IPCAF) is a tool to support the implementation of the World Health Organization (WHO) Guidelines on core components of IPC programmes at the acute health care facility level. The user should be familiar with the contents of these guide... more

Download (94)

View PDF (1677)

Core components for IPC - Implementation tools and resources

World Health Organization WHO (2020) C_WHO

Based on scientific evidence, expert consensus and country experiences, the WHO core components for infection prevention and control (IPC) are the foundation for establishing or strengthening effective programmes at the national and facility level. These new guidelines on core components of infecti... more

Download (372)

View PDF (301)

Decontamination and reprocessing of medical devices for health care facilities: aide-memoire

World Health Organization WHO (2022) CC

Decontamination of medical devices plays an important role in the prevention of health care-associated infections. It includes cleaning, disinfection and/or sterilization. The processes involved in decontamination are complex, require specific infrastructure and equipment, and involve several sequen... more

Download (246)

View PDF (174)

World Health Organization strategy (‎2022-2026)‎ for the National Action Plan for Health Security

World Health Organisation (WHO) (2023) C_WHO

This strategy defines the World Health Organization (WHO) vision and framework for supporting Member States to accelerate the development, implementation and monitoring of their National Action Plan for Health Security (NAPHS) from 2022 to 2026. The National Action Plan for Health Security (NAPHS) ... more

Download (103)

View PDF (635)

Reimagining the fight against Chagas disease

Novartis (2020) C1

Chagas disease affects approximately 6 million people, mainly in Latin America. Less than 1% of affected individuals receive proper antiparasitic treatment, and current drugs are inadequate to fight the entire spectrum of the disease. Against this background, Novartis is pursuing an end-to-end appro... more

Download (80)

View PDF (858)

Surveillance data for human leishmaniasis indicate the need for a sustainable action plan for its management and control, Greece, 2004 to 2018

Tzani M., Barrasa, A., Vakali, A. et al. Euro Surveillance (2020) CC

Leishmaniasis is a parasitic disease caused by intracellular protozoan parasites of the genus Leishmania (Trypanosomatidae family); it is endemic in more than 98 countries worldwide [1]. Visceral (VL) and cutaneous (CL) leishmaniasis are the most common forms of the disease. VL causes a systemic dis... more

Download (164)

View PDF (201)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (121)

View PDF (538)

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes (Second edition)
recommended

World Health Organization WHO (2023) C_WHO

This toolkit provides step-by-step guidance to NTD programme managers and partners on how to engage and work collaboratively with the WASH community to improve delivery of water, sanitation and hygiene services to underserved population affected by many neglected tropical diseases. The toolkit draws... more

Download (131)

View PDF (165)

Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050

Global Burden of Disease Health Financing Collaborator Network The Lancet (2019) CC

Comprehensive and comparable estimates of health spending in each country are a key input for health policy and planning, and are necessary to support the achievement of national and international health goals. Previous studies have tracked past and projected future health spending until 2040 and ... more

Download (214)

View PDF (153)

Responding to communicable and noncommunicable diseases: progress report 2020-2022

World Health Organisation (WHO) (2023) C_WHO

Significant progress has been made in the eradication of three priority diseases in the African Region, as a result of extensive collaboration between the Regional Office, WHO country offices and countries. For example, in August 2020, the region was certified free of wild poliovirus. In the area of... more

Download (252)

View PDF (295)

Community Engagement During Public Health Emergencies Like COVID-19: An Action Framework and Toolkit

Bangladesh Red Crescent Society; BRAC; Government of Bangladesh; UN Children's Fund UNICEF; UN Women; World Health Organization WHO (2023) CC

This handbook offers a simple framework of action for actors in local government, and in particular, health leaders such as Civil Surgeons (CSs) and Upazila Health and Family Planning Officers (UHFPQOs), to take ownership and leadership to combat COVID-19 at each district and upazila respectively, w... more

Download (319)

View PDF (159)

Infection Prevention and Control Standard Operating Procedures For Cholera Treatment Centres and Units in Malawi (April 2023)

Africa Centres for Disease Control and Prevention Africa CDC; African Union; Government of Malawi; Médecins Sans Frontières; UN Children's Fund UNICEF; World Health Organization WHO (2023) CC

Infection prevention and control (IPC) in a CTC/ CTU IPC are all practical measures taken in the healthcare facility to prevent harm caused by infections to patients, health workers and communities. The main goal of IPC in the cholera response is to • To reduce transmission of health care-as... more

Download (176)

View PDF (153)

Policy brief on tuberculosis-associated disability

World Health Organization WHO (2023) C_WHO

People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (296)

View PDF (126)

Managing epidemics: key facts about major deadly diseases, 2nd edition

World Health Organisation (WHO) (2023) C_WHO

Epidemics and pandemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of new... more

Download (112)

View PDF (108)

Managing epidemics: key facts about major deadly diseases, 2nd edition

World Health Organisation (WHO) (2023) C_WHO

Guidelines on core components of infection prevention and control programmes recommended

Infection Prevention and Control Assessment Framework at the Facility Level recommended

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes (Second edition) recommended

Guidelines on core components of infection prevention and control programmes
recommended

Infection Prevention and Control Assessment Framework at the Facility Level
recommended

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes (Second edition)
recommended